Marshall Wace’s Capricor Therapeutics CAPR Stock Holding History

Marshall Wace’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.33M	Sell	109,531 -12,381	-10%	-$330K	﹤0.01%	1517
2025 Q4	$3.52M	Buy	121,912 +22,799	+23%	+$298K	﹤0.01%	1316
2025 Q3	$715K	Buy	99,113 +18,926	+24%	+$139K	﹤0.01%	2091
2025 Q2	$796K	Buy	+80,187	New	+$847K	﹤0.01%	1946
2025 Q1	–	Sell	-59,303	Closed	-$818K	–	2648
2024 Q4	$818K	Buy	+59,303	New	+$1.04M	﹤0.01%	1823
2024 Q3	–	Sell	-89,314	Closed	-$426K	–	2538
2024 Q2	$426K	Buy	+89,314	New	+$498K	﹤0.01%	2019
2023 Q1	–	Sell	-28,359	Closed	-$109K	–	2695
2022 Q4	$109K	Buy	+28,359	New	+$135K	﹤0.01%	2779

Other funds holding CAPR

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JHC

Jones Hill Capital New York $466M AUM

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Marshall Wace's CAPR Position: Q1 2026 in Review

Marshall Wace reduced its Capricor Therapeutics (CAPR) stake by 10% in Q1 2026, selling an estimated $330K and leaving 109,531 shares worth $3.33M. The position accounts for ﹤0.01% of the portfolio, ranked #1517.

Marshall Wace first reported a position in CAPR in Q4 2022 and has held it in 7 quarters since. The position peaked at $3.52M in Q4 2025. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.

Marshall Wace held 109,531 shares of Capricor Therapeutics worth $3.33M as of Q1 2026.
Marshall Wace sold 12,381 Capricor Therapeutics shares in Q1 2026, an estimated $330K.
Capricor Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #1517 holding.
Marshall Wace first reported a position in Capricor Therapeutics in Q4 2022 and has held it in 7 quarters since.
Marshall Wace's Capricor Therapeutics position peaked at $3.52M in Q4 2025.
177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.